MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud

Reuters12-02

<a href="https://laohu8.com/S/MLTX">MoonLake Immunotherapeutics</a> Faces Class Action Lawsuit Alleging Securities Fraud

A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide a superior clinical benefit or increased tissue penetration compared to traditional monoclonal antibodies. As a result, the lawsuit contends that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over monoclonal antibodies. Investors who believe they were affected by these actions are encouraged to seek legal advice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113708) on December 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588205822?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588205822","market":"fut","top_or_hot":-1,"title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> Faces Class Action Lawsuit Alleging Securities Fraud\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide a superior clinical benefit or increased tissue penetration compared to traditional monoclonal antibodies. As a result, the lawsuit contends that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over monoclonal antibodies. Investors who believe they were affected by these actions are encouraged to seek legal advice.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113708) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 20:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> Faces Class Action Lawsuit Alleging Securities Fraud\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide a superior clinical benefit or increased tissue penetration compared to traditional monoclonal antibodies. As a result, the lawsuit contends that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over monoclonal antibodies. Investors who believe they were affected by these actions are encouraged to seek legal advice.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113708) on December 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLTX","symbol_name":"MoonLake Immunotherapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL3fxjWs:1","article_id":"2588205822","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588205822","pubTimestamp":1764679331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide a superior clinical benefit or increased tissue penetration compared to traditional monoclonal antibodies. As a result, the lawsuit contends that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over monoclonal antibodies. Investors who believe they were affected by these actions are encouraged to seek legal advice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLTX":"MoonLake Immunotherapeutics","BK4139":"生物科技"},"translate_title":"MoonLake Immunotherapeutics面临指控证券欺诈的集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9},"content_text":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Alleging Securities Fraud\n    \n\n        A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024, and September 29, 2025. The complaint alleges that the company made false statements or concealed information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure does not provide a superior clinical benefit or increased tissue penetration compared to traditional monoclonal antibodies. As a result, the lawsuit contends that the company lacked a reasonable basis for its positive statements about SLK's purported advantages over monoclonal antibodies. Investors who believe they were affected by these actions are encouraged to seek legal advice.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113708) on December 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588205822","isCrawlerRequest":true}